News | May 02, 2026
Dr Lal PathLabs posts strong Q4 FY26 results with 16.6% revenue growth & PAT at Rs. 132 Cr
The company posted revenue of Rs. 703 crore in Q4 FY26
The company posted revenue of Rs. 703 crore in Q4 FY26
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
The company allocated €56 million to research and development for next-generation line solutions
Subscribe To Our Newsletter & Stay Updated
